BURLINGTON, Mass., Sept. 30 /PRNewswire/ — Decision Resources,
one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that, according to
surveyed European oncologists, Johnson & Johnson’s abiraterone
will capture greater patient share than Dendreon’s Provenge,
AstraZeneca’s zibotentan or Bristol-Myers Squibb’s ipilimumab in
asymptomatic or minimally symptomatic, metastatic
castrate-resistant prostate cancer (MCRPC).
According to the new European Physician & Payer Forum report
entitled Will Emerging Agents for Prostate Cancer Achieve
Acceptance from Payers and Prescribers in Europe?, surveyed
oncologists in France, Germany, Italy, Spain and the United Kingdom
say that efficacy is overwhelmingly the most important factor
dictating the uptake of emerging therapies for MCRPC.
“Emerging agents need to improve efficacy over current standards
of care in order to penetrate the market,” said Decision Resources
Analyst Andrew Merron, Ph.D. “The barrier is lower in the
asymptomatic MCRPC setting where clinicians are dependent on
hormonal therapies, while barriers are greater in the symptomatic
MCRPC setting where Sanofi-Aventis’s Taxotere (docetaxel), the
gold-standard, is widely prescribed. As a result, most agents in
clinical trials are being used in combination with Taxotere for
symptomatic MCRPC.”
In symptomatic MCRPC, the majority of patients will receive a
Taxotere-containing regimen one year following the launch of
emerging therapies. Celgene’s Revlimid and Bristol-Myers Squibb’s
Sprycel and zibotentan will compete to partner with Taxotere. After
considering reimbursement hurdles in their countries, overall,
French and Italian oncologists assign the greatest patient share to
Sprycel and zibotentan. However, the greatest patient share of any
regimen will be attributed to Taxotere/prednisone alone with no
emerging therapy additions.
In non-metastatic castrate-resis
‘/>”/>